In many ways, the human body is like any other machine in that it requires constant refueling and maintenance to keep functioning. Much of this happens without our intervention beyond us selecting what to eat that day. There are however times when due to an accident, physical illness or aging the automatic repair mechanisms of our body become overwhelmed, fail to do their task correctly, or outright fall short in repairing damage.
Most of us know that lizards can regrow tails, some starfish regenerate into as many new starfish as the pieces which they were chopped into, and axolotl can regenerate limbs and even parts of their brain. Yet humans too have an amazing regenerating ability, although for us it is mostly contained within the liver, which can regenerate even when three-quarters are removed.
In the field of regenerative medicine, the goal is to either induce regeneration in damaged tissues, or to replace damaged organs and tissues with externally grown ones, using the patients own genetic material. This could offer us a future in which replacement organs are always available at demand, and many types of injuries are no longer permanent, including paralysis.
Our level of understanding of human physiology and that of animals in general has massively expanded since the beginning of the 20th century when technology allowed us to examine the microscopic world in more detail than ever before. Although empirical medical science saw its beginnings as early as the Sumerian civilization of the 3rd millennium BCE, our generalized understanding of the processes and components that underlie the bodys functioning are significantly more recent.
DNA was first isolated in 1869 by Friedrich Miescher, but its structure was not described until 1953. This discovery laid the foundations for the field of molecular biology, which seeks to understand the molecular basis for biological activity. In a sense this moment can be seen as transformative as for example the transition from classical mechanics to quantum mechanics, in that it changed the focus from macroscopic observations to a more fundamental understanding of these observations.
This allowed us to massively increase our understanding of how exactly the body responds to damage, and the molecular basis for regenerative processes, as well as why humans are normally not able to regrow damaged limbs. Eventually in 1999 the term regenerative medicine was coined by William A. Haseltine, who wrote an article in 2001 on what he envisions the term to include. This would be the addressing of not only injuries and trauma from accidents and disease, but also aging-related conditions, which would address the looming demographic crisis as the average age of the worlds populations keeps increasing.
The state of the art in regenerative medicine back in 2015 was covered by Angelo S. Mao et al. (2015). This covers regenerative methods involving either externally grown tissues and organs, or the stimulating of innate regenerative capabilities. Their paper includes the biomedical discipline of tissue engineering due to the broad overlap with the field of regenerative medicine. Despite the very significant time and monetary requirement to bring a regenerative medicine product to market, Mao et al. list the FDA-approved products at that time:
While these were not miracle products by any stretch of the imagination, they do prove the effectiveness of these approaches, displaying similar or better effectiveness as existing products. While getting cells to the affected area where they can induce repair is part of the strategy, another essential part involves the extracellular matrix (ECM). These are essential structures of many tissues and organs in the body which provide not only support, but also play a role in growth and regeneration.
ECM is however non-cellular, and as such is seen as a medical device. They play a role in e.g. the healing of skin to prevent scar tissue formation, but also in the scaffolding of that other tantalizing aspect of regenerative medicine: growing entire replacement organs and body parts in- or outside of the patients body using their own cells. As an example, Mase Jr, et al. (2010) report on a 19-year old US Marine who had part of his right thigh muscle destroyed by an explosion. Four months after an ECM extracted from porcine (pig) intestinal submucossa was implanted in the area, gradual regrowth of muscle tissue was detected.
An important research area here is the development of synthetic ECM-like scaffolding, as this would make the process faster, easier and more versatile. Synthetic scaffolding makes the process of growing larger structures in vitro significantly easier as well, which is what is required to enable growing organs such as kidneys, hearts and so on. These organs would then ideally be grown from induced pluropotent stem cells (iPS), which are a patients own cells that are reverted back to an earlier state of specialization.
It should come as little surprise that as a field which brings together virtually every field that touches upon (human) biology in some fashion, regenerative medicine is not an easy one. While its one thing to study a working system, its a whole different level to get one to grow from scratch. This is why as great as it would be to have an essentially infinite supply of replacement organs by simply growing new ones from iPS cells, the complexity of a functional organ makes this currently beyond our reach.
Essentially the rule is that the less complicated the organ or tissue is, the easier it is to grow it in vitro. Ideally it would just consist out of a single type of cell, and happy develop in some growth medium without the need for an ECM. Attractive targets here are for example the cornea, where the number of people on a waiting list for a corneal transplant outnumber donor corneas significantly.
In a review by Mobaraki et al. (2019), the numerous currently approved corneal replacements as well as new methods being studied are considered. Even though artificial corneas have been in use for years, they suffer from a variety of issues, including biocompatibility issues and others that prevent long-term function. Use of donor corneas comes with shortages as the primary concern. Current regenerative research focuses on the stem cells found in the limbus zone (limbal stem cells, LSC). These seem promising for repairing ocular surface defects, which has been studied since 1977.
LSCs play a role in the regular regenerative abilities of the cornea, and provide a starting point for either growing a replacement cornea, or to repair a damaged cornea, along with the addition of an ECM as necessary. This can be done in combination with the inhibiting of the local immune response, which promotes natural wound healing. Even so, there is still a lot more research that needs to be performed before viable treatments for either repairing the cornea in situ, or growing a replacement in vitro can be approved the FDA or national equivalent.
A similar scenario can be seen with the development of artificial skin, where fortunately due to the large availability of skin on a patients body grafts (autografts) are usually possible. Even so, the application of engineered skin substitutes (ESS) would seem to be superior. This approach does not require the removal of skin (epidermis) elsewhere, and limits the amount of scar formation. It involves placing a collagen-based ECM on the wound, which is optionally seeded with keritanocytes (skin precursor cells), which accelerates wound closure.
Here the scaffolding proved to be essential in the regeneration of the skin, as reported by Tzeranis et al. (2015). This supports the evidence from other studies that show the cell adhesion to the ECM to be essential in cell regulation and development. With recent changes, it would seem that both the formation of hair follicles and nerve innervation may be solved problems.
It will likely still be a long time before we can have something like a replacement heart grown from a patients own iPS cells. Recent research has focused mostly on decellularization (leaving only the ECM) of an existing heart, and repopulating it with native cells (e.g. Glvez-Montn et al., 2012). By for example creating a synthetic scaffold and populating it with cells derived from a patients iPS cells, a viable treatment could be devised.
Possibly easier to translate into a standard treatment is the regrowth of nerves in the spinal cord after trauma, with a recent article by lvarez et al, (2021) (press release) covering recent advances in the use of artificial scaffolds that promotes nerve regeneration, reduces scarring and promotes blood vessel formation. This offers hope that one day spinal cord injures may be fully repairable.
If we were to return to the body as a machine comparison, then the human body is less of a car or piece of heavy machinery, and more of a glued-together gadget with complex circuitry and components inside. With this jump in complexity comes the need for a deeper level of understanding, and increasingly more advanced tools so that repairs can be made efficiently and with good outcomes.
Even so, regenerative medicine is already saving the lives of for example burn victims today, and improving the lives of countless others. As further advances in research continue to translate into treatments, we should see a gradual change from youll have to learn to live with that, to a more optimistic give it some time to grow back, as in the case of an injured veteran, or the victim of an accident.
- Japan univ. uses iPS cells to treat spinal cord injury for 1st time - Kyodo News Plus - January 16th, 2022
- Electrophysiological measures from human iPSC-derived neurons are associated with schizophrenia clinical status and predict individual cognitive... - January 13th, 2022
- Cell Therapy Processing Market CAGR of 27.80% Share, Scope, Stake, Trends, Industry Size, Sales & Revenue, Growth, Opportunities and Demand with... - December 31st, 2021
- Proteomic mapping of atrial and ventricular heart tissue in patients with aortic valve stenosis | Scientific Reports - Nature.com - December 25th, 2021
- Nobel laureate Yamanaka to retire as director of iPS cell center | The Asahi Shimbun: Breaking News, Japan News and Analysis - Asahi Shimbun - December 11th, 2021
- Stem Cells Applications in Regenerative Medicine and ... - November 13th, 2021
- Spinal cord injuries: how could stem cells help ... - November 13th, 2021
- Second type of cancer treatment using iPS cells starts in Chiba | The Asahi Shimbun: Breaking News, Japan News and Analysis - Asahi Shimbun - November 13th, 2021
- Shinya Yamanaka - Facts - NobelPrize.org - November 5th, 2021
- Telomerase reverse transcriptase - Wikipedia - November 5th, 2021
- Curi Bio and NEXEL Announce Celogics, Joint Venture to Develop Leading iPSC-derived Cell Products - Business Wire - November 1st, 2021
- Diabetes - A Closer Look at Stem Cells - November 1st, 2021
- The therapeutic potential of stem cells - October 23rd, 2021
- RxCell Inc., A*STAR's IMCB, NUS, and SERI Collaborate to Develop Cellular Therapeutics for Age-related Diseases - Business Wire - October 13th, 2021
- Singapore-US to develop cellular therapeutics for age-related diseases - BSA bureau - October 13th, 2021
- Artisan Bio to present CRISPR-engineered cell therapies at Meeting on the Mesa - PRNewswire - October 13th, 2021
- Bone Therapeutics appoints Scientific Advisory Board for iMSC cell and gene therapy platform development - GlobeNewswire - October 13th, 2021
- Stem Cells & Therapies Archives - Charlotte Lozier Institute - October 5th, 2021
- Stem Cells - University of Utah - October 5th, 2021
- Drug that stops ALS progression found using iPS cells from patients - Japan Today - October 5th, 2021
- Stem Cell Research | Uses of Stem Cells and Ethics ... - October 5th, 2021
- Japan's Fujifilm promotes industrial application of iPS cell-derived regenerative medicine - BSA bureau - October 5th, 2021
- Drug that stops ALS progression found using iPS cells from patients - The Japan Times - October 3rd, 2021
- Bone Therapeutics signs research partnership with Implant Therapeutics to access induced Pluripotent Stem Cells (iPSC) - Yahoo Finance - September 29th, 2021
- Development of alveolar and airway cells from human iPS cells: toward SARS-CoV-2 research and drug toxicity testing - DocWire News - September 4th, 2021
- Roslin Tech in multi-million bid to fund sustainable food - HeraldScotland - September 1st, 2021
- Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma -... - August 20th, 2021
- DAILY DOSE: August 18, 2021 - Sovereign Wealth Fund Institute - August 20th, 2021
- Stem Cell Therapy Market worth $40.3 billion by 2027 Exclusive Report by CoherentMarketInsights - PharmiWeb.com - August 18th, 2021
- Beam Therapeutics Provides Business and Pipeline Updates and Reports Second Quarter 2021 Financial Results - Yahoo Finance - August 14th, 2021
- Asia-Pacific Cell Therapy Market 2021-2028 - Opportunities in the Approval of Kymriah and Yescarta - PRNewswire - August 8th, 2021
- Stem cells ppt - SlideShare - July 27th, 2021
- Stem cell therapy for retinal degeneration | BTT - Dove Medical Press - July 27th, 2021
- Stem cells: a brief history and outlook - Science in the News - July 15th, 2021
- Pluripotent Stem Cells 101 Boston Children's Hospital - July 15th, 2021
- Induced Pluripotent Stem Cells: The Future of Tissue ... - July 15th, 2021
- Stem Cells | National Institutes of Health (NIH) - July 15th, 2021
- Wicker Challenges Biden Administration Over Research Using Aborted Infants - Yall Politics - June 29th, 2021
- Regenerative Medicine Bets on iPS Stem Cells - GoodCell - June 16th, 2021
- Stem Cells - Sigma-Aldrich - June 16th, 2021
- Nobel laureate calls for research funds to solve the mystery of aging : The Asahi Shimbun - Asahi Shimbun - May 26th, 2021
- Kyoto team creates 'killer T cells' that fight cancer without immune reaction - The Mainichi - The Mainichi - May 20th, 2021
- Accelerated Biosciences' Immune-Privileged Human Trophoblast Stem Cells (hTSCs) Offer Breakthrough Opportunities in Cancer-Targeting Therapeutics and... - May 12th, 2021
- The Induced Pluripotent Stem Cells Market To Witness A Spike Amidst Entry Of New Players - Industry Today - May 7th, 2021
- Induced Pluripotent Stem Cells (iPSCs) Market 2021 Industry Size, Share, Growth and Top Companies Analysis- Fujifilm Holding Corporation (CDI),... - April 30th, 2021
- Induced Pluripotent Stem Cells (iPSCs) Market 2021 Is Booming Across the Globe by Share, Size, Growth, Segments and Forecast to 2027 | Top Players... - April 30th, 2021
- Global Induced Pluripotent Stem Cells Market Analysis By Future Demand, Top Players, Industry Share Size, Revenue and Growth Rate Through... - April 30th, 2021
- Global Stem Cell Therapy Market 2020-2027 Trends, industry vertical, along with the geography, delivering valuable insights | Reportspedia Clark... - April 30th, 2021
- Synthego Launches Eclipse Platform to Accelerate Research and Development of Next-generation Medicines - The Scientist - April 16th, 2021
- Global Induced Pluripotent Stem Cell (iPS Cell) Market Report 2021: In Total, At Least 68 Distinct Market Competitors Now Offer Various Types of iPSC... - April 16th, 2021
- Synthego Launches The Eclipse Platform to Accelerate Research and Development of Next-generation Medicines - PRNewswire - April 8th, 2021
- NCRAD: Increasing infrastructure for Alzheimer's disease researchers | National Institute on Aging - National Institute on Aging - April 1st, 2021
- Modeling the Human Lung with Organoids - The Scientist - April 1st, 2021
- Kyoto University to supply iPS cells from COVID-19 survivors for research - The Japan Times - March 26th, 2021
- Mini-brains show why human brains grow larger than those of other apes - New Scientist News - March 26th, 2021
- Key human embryo stage mimicked in the lab - Science Magazine - March 20th, 2021
- Pluripotent Stem Cells (iPS Cells) | Thermo Fisher ... - March 18th, 2021
- Science and blastocysts - Cosmos - March 18th, 2021
- Human induced pluripotent stem cells - Takara Bio - March 11th, 2021
- iPS Cell Research // Center for Stem Cells and ... - March 11th, 2021
- What are induced pluripotent stem cells or IPS cells ... - March 11th, 2021
- IPS Cells | Everything You Need To Know | BioInformant - March 11th, 2021
- Glial Cell Discovery Could Point the Way to Motor Neuron Disease Therapies - Technology Networks - March 11th, 2021
- Peer Recognition | The UCSB Current - The UCSB Current - March 11th, 2021
- Fetal Cell Lines Were Used to Make the Johnson & Johnson COVID VaccineHeres What That Means - Health.com - March 5th, 2021
- Induced Pluripotent Stem Cells Reveal Causes of Disease - Technology Networks - March 5th, 2021
- Pericardial Injection Effective, Less Invasive Way to Get Regenerative Therapies to Heart - NC State News - March 5th, 2021
- Organoids of human lung and brain respond differently to SARS-CoV-2 - BioNews - March 5th, 2021
- Study explores individual differences of SARS-CoV-2 infection in ACE2-expressing stem cells - News-Medical.Net - February 27th, 2021
- Promoting Stem Cell Growth and Self-Renewal In Vitro - The Scientist - February 25th, 2021
- Induced Pluripotent Stem Cells Market Growth, Competitive Landscape, Research Methodology, Business Opportunities, Statistics and Industry Analysis... - February 17th, 2021
- Induced Pluripotent Stem Cells Market Growth Opportunities, Analysis and Forecasts Report 2020-2026 with key players position (Fujifilm Holding... - February 17th, 2021
- Global Induced Pluripotent Market Positive Outlook, Revenue Generation & Leading Manufacturers, Forecast 2026||CELGENE CORPORATION; Astellas... - February 17th, 2021
- Can we freeze them? Yes we can, says Nkarta - Vantage - February 17th, 2021
- Outlook on the Cell Therapy Global Market to 2027 - Opportunity Analysis and Industry Forecasts - Yahoo Finance - February 10th, 2021
- Breakthrough stem cell therapy may reverse life-threatening conditions in dogs - Study Finds - February 10th, 2021
- Global Allogenic Stem Cell Therapy Market Opportunities, Ongoing Trends And Key Players 2027||Thermo Fisher Scientific., Cellular Engineering... - January 24th, 2021
- Induced Pluripotent Stem Cells (iPSCs) Market to Witness Massive Growth During 2021-2027 | Fujifilm Holding Corporation (CDI), Ncardia, Sumitomo... - January 24th, 2021
- DiNAQOR Acquires EHT Technologies GmbH to Advance Engineered Heart Tissue R&D Capabilities - PRNewswire - January 24th, 2021
- Induced Pluripotent Stem Cells Market Segmentation and Analysis by Latest Trends, Development and Growth by Trending Regions 2020 with key players... - January 24th, 2021